About this Research Topic
The convergence of wider availability of pharmacogenomic testing in healthcare settings with advances in implementation science and a growing panel of actionable high-level evidence for clinical utility presents an exciting opportunity to advance precision health for all. But first, many societal and systems-based barriers need to be systematically and thoughtfully addressed to benefit all populations. Early-adopting healthcare systems of pharmacogenomic clinical applications are making major inroads in achieving scalable, risk-based, and population-based implementation, and digital medicine. Can the wider scientific and healthcare communities in the international community learn from these models of success? Can community-based participatory research inform more equitable precision health? Has preemptive pharmacogenomic testing demonstrated clinical utility in improving measurable health outcomes, and if so, which patient populations derive the most benefit from testing? For this Research Topic in Frontiers in Pharmacology, we invite original research, methods, and other papers that highlight the frontiers of this emerging field.
This Research Topic addresses the remaining opportunity gaps to widespread pharmacogenomics implementation and how successful healthcare-based and population-based programs have demonstrated success in tackling a range of barriers to implementation.
We are interested in highlighting recent advances and beacon programs addressing:
1) Healthcare systems that have leveraged biomedical informatics approaches – including natural language processing, machine learning, and artificial intelligence—to operationalize patient risk stratification and pharmacogenetically informed preventive care
2) Reducing the disease burden of disease of adverse drug reactions through preemptive genotyping to guide drug selection and genotype-informed dosing
3) Impact of pharmacogenomic testing on medical outcomes for complex, chronic diseases like type 2 diabetes, hypertension, hypertension, hyperlipidemia, and depression
4) Cost-effectiveness and other economic models that demonstrate the value proposition of pharmacogenomic testing for healthcare systems
5) Population-based testing and community-engaged approaches to improve the inclusion of underserved and underrepresented patient communities
6) Descriptions of programs with sustainable business models that are transportable to other organizations
We are inviting authors to submit papers that cover the landscape of innovation in pharmacogenomics implementation. These themes and formats include:
• Original research including multi-omics and pharmacogenomics studies that measure medical outcomes and systems outcomes
• Health economic research demonstrating the cost-effectiveness of preemptive testing
• Community or population-based implementation studies addressing health equity
• Mixed-methods research addressing barriers to access or acceptance of pharmacogenomic testing
• Methods, commentaries, and white papers on the state of the science of pharmacogenomic implementation from health systems to communities
Please note that:
• If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria,
inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
• If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
• Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
Dr. Sean David is a shareholder at Genalyte Inc., a San Diego, CA-based start-up that does laboratory testing, but not genetic testing. It is mentioned here for transparency.
This Research Topic addresses the remaining opportunity gaps to widespread pharmacogenomics implementation and how successful healthcare-based and population-based programs have demonstrated success in tackling a range of barriers to implementation.
We are interested in highlighting recent advances and beacon programs addressing:
1) Healthcare systems that have leveraged biomedical informatics approaches – including natural language processing, machine learning, and artificial intelligence—to operationalize patient risk stratification and pharmacogenetically informed preventive care
2) Reducing the disease burden of disease of adverse drug reactions through preemptive genotyping to guide drug selection and genotype-informed dosing
3) Impact of pharmacogenomic testing on medical outcomes for complex, chronic diseases like type 2 diabetes, hypertension, hypertension, hyperlipidemia, and depression
4) Cost-effectiveness and other economic models that demonstrate the value proposition of pharmacogenomic testing for healthcare systems
5) Population-based testing and community-engaged approaches to improve the inclusion of underserved and underrepresented patient communities
6) Descriptions of programs with sustainable business models that are transportable to other organizations
We are inviting authors to submit papers that cover the landscape of innovation in pharmacogenomics implementation. These themes and formats include:
• Original research including multi-omics and pharmacogenomics studies that measure medical outcomes and systems outcomes
• Health economic research demonstrating the cost-effectiveness of preemptive testing
• Community or population-based implementation studies addressing health equity
• Mixed-methods research addressing barriers to access or acceptance of pharmacogenomic testing
• Methods, commentaries, and white papers on the state of the science of pharmacogenomic implementation from health systems to communities
Please note that:
• If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria,
inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
• If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
• Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
Dr. Sean David is a shareholder at Genalyte Inc., a San Diego, CA-based start-up that does laboratory testing, but not genetic testing. It is mentioned here for transparency.
Keywords: Pharmacogenetics, Pharmacogenomics, Implementation Science, Clinical Implementation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
